中国药物警戒 ›› 2026, Vol. 23 ›› Issue (7): 826-828.
DOI: 10.19803/j.1672-8629.20260143

• 安全与合理用药 • 上一篇    下一篇

氟泽雷塞片致重度药物性肝损伤1例分析

姜伟1,3, 后开凤2, 许磊4, 丁丽3, 许莹莹3, 葛海林3, 王君萍1, 江洁美3,*   

  1. 1中国科学院合肥肿瘤医院药学中心,安徽 合肥 230031;
    2中国科学院合肥肿瘤医院淋巴瘤科,安徽 合肥 230031;
    3安徽医科大学第一附属医院药剂科,安徽 合肥 230031;
    4安徽医科大学第一附属医院肿瘤放疗科,安徽 合肥 230031
  • 收稿日期:2026-02-12 出版日期:2026-07-15 发布日期:2026-07-16
  • 通讯作者: *江洁美,女,硕士,副教授,临床药学。E-mail：jjimei1213@163.com
  • 作者简介:姜伟,女,硕士,主管药师,临床药学。
  • 基金资助:
    安徽省卫生健康委科研项目（AHWJ2023BAa10001）; 安徽省教育厅高等学校省级质量工程项目（2024jyxm0725）

One case of severe hepatotoxicity caused by fulzerasib tables

Jiang Wei1,3, Hou Kaifeng2, Xu Lei4, Ding Li3, Xu Yingying3, Ge Hailin3, Wang Junping1, Jiang Jiemei3,*   

  1. 1Hefei Cancer Hospital, Chinese Academy of Sciences, Pharmacy Center, Hefei Anhui 230031, China;
    2Hefei Cancer Hospital, Chinese Academy of Sciences, Lymphoma, Hefei Anhui 230031, China;
    3Department of Pharmacy, the First Affiliated Hospital of Anhui Medical University, Hefei Anhui 230031, China;
    4Department of Radiation Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei Anhui 230031, China
  • Received:2026-02-12 Online:2026-07-15 Published:2026-07-16

PDF (PC)

13

摘要： 目的 探讨氟泽雷塞片所致药物性肝损伤（Drug-Induced Liver Injury, DILI）的风险因素、可能机制和治疗策略,为临床安全用药提供参考。方法 分析1例氟泽雷塞片治疗晚期非小细胞肺癌的病例,对靶向药物引发的DILI进行鉴别,深入探讨其发生机制及针对性治疗策略。结果 患者经氟泽雷塞片治疗后发生重度胆汁淤积型DILI,关联性评价为“很可能”,经停药、保肝利胆等治疗后,患者肝功能指标显著改善。结论 临床使用抗肿瘤药物应重视肝毒性相关风险,发生DILI需及时停药和对症处理。

关键词: 氟泽雷塞片, 靶向治疗, 非小细胞肺癌, 胆汁淤积型, 药物性肝损伤, 肝毒性, 药品不良反应

Abstract: Objective To investigate the risk factors, potential mechanisms and therapeutic strategies related to drug-induced liver injury (DILI) caused by fulzerasib tablets so as to provide references for safe clinical medication. Methods One case of advanced non-small cell lung cancer treated with fulzerasib tablets was analyzed, DILI induced by targeted drugs was identified, and the pathogenesis and targeted therapeutic strategies were explored. Results The patient developed severe cholestatic DILI after treatment with fulzerasib tablets. Causality assessment suggested the association with fulzerasib was “probable”. After drug discontinuation and hepatoprotective and cholagogic treatment, the patient’s indicators of liver function were significantly improved. Conclusion Risk factors for hepatotoxicity during clinical use of antineoplastic drugs deserve attention. In case of adverse reactions of DILI, quick drug withdrawal and symptomatic treatment are critical.

Key words: Fulzerasib Tablets, Targeted Therapy, Non-Small Cell Lung Cancer, Cholestatic, Drug-Induced Liver Injury(DILI), Hepatotoxicity, Adverse Drug Reaction

中图分类号: